Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

@inproceedings{Cremers2016PrognosticPF,
  title={Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT},
  author={Eline M. P. Cremers and Anja A van Biezen and L. C. de Wreede and Marjolein A Scholten and Anton{\'i}n V{\'i}tek and Julie Finke and Uwe- Platzbecker and Dietrich W. Beelen and Rainer Schwerdtfeger and Liisa Volin and Nikolaos Harhalakis and Nicole Ma Blijlevens and Arnon Nagler and Nicolaus Kr{\"o}ger and Tim de Witte},
  booktitle={Annals of Hematology},
  year={2016}
}
Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS). However, patient cohorts are often heterogeneous by disease stage and treatment modalities, which complicates interpretation of the results. This study aimed to obtain a homogeneous patient cohort by including only de novo MDS patients who received upfront allogeneic SCT after standard high dose myelo-ablative conditioning. The effect of pre… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…